These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11233917)

  • 1. Transfusion of peripheral blood stem cells from donor homozygous for a shared HLA-haplotype: avoiding fatal transfusion-associated graft-versus-host disease while preserving anti-leukemic effect.
    Wong R; Lau FY; Chui CH; Tsang KS; Chik KW; Li CK; Cheng G
    Transplantation; 2001 Feb; 71(3):487-90. PubMed ID: 11233917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The critical role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease in immunocompetent patients.
    Otsuka S; Kunieda K; Kitamura F; Misawa K; Sasaoka I; Hirose M; Kasuya S; Saji S; Noma A
    Transfusion; 1991; 31(3):260-4. PubMed ID: 2003327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors.
    Benson K; Marks AR; Marshall MJ; Goldstein JD
    Transfusion; 1994 May; 34(5):432-7. PubMed ID: 8191569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings.
    Morishima Y; Morishima S; Murata M; Arima N; Uchida N; Sugio Y; Takahashi S; Matsuhashi Y; Onizuka M; Eto T; Nagafuji K; Onishi Y; Inoue M; Atsuta Y; Fukuda T; Ichinohe T; Kato S; Kanda J
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):132-138. PubMed ID: 31521817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease.
    Shivdasani RA; Anderson KC
    Leuk Lymphoma; 1994 Oct; 15(3-4):227-34. PubMed ID: 7866271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
    Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.
    Kanda J; Ikegame K; Fuji S; Kurokawa M; Kanamori H; Fukuda T; Ohashi K; Ishikawa J; Ogawa H; Inoue M; Ichinohe T; Atsuta Y; Kanda Y;
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2031-2037. PubMed ID: 27492794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients.
    Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M
    Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
    Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
    Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells.
    Triulzi D; Duquesnoy R; Nichols L; Clark K; Jukic D; Zeevi A; Meisner D
    Transfusion; 2006 Jun; 46(6):885-8. PubMed ID: 16734803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transplantation of highly purified CD34+ hematologic peripheral stem cells from haploidentical related donors in the treatment of children with non-malignant diseases].
    Starý J; Sedlácek P; Vodvárková S; Poloucková A; Formánková R; Gasová Z; Marinov I
    Cas Lek Cesk; 2002 Mar; 141(6):176-81. PubMed ID: 11977835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of HLA Homozygous Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation.
    Morishima Y; Azuma F; Kashiwase K; Matsumoto K; Orihara T; Yabe H; Kato S; Kato K; Kai S; Mori T; Nakajima K; Morishima S; Satake M; Takanashi M; Yabe T;
    Stem Cells Transl Med; 2018 Feb; 7(2):173-179. PubMed ID: 29274116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.